Back Link
Reader View

Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031

www.cnbc.com · November 19, 2026 · 08:33

Drugmaker Novartis raised its peak sales forecast for three of its best-selling drugs on Thursday, citing strong demand as it looks to offset the financial impact of older drugs' patent expiries.

The Swiss drugmaker now expects multiple sclerosis drug Kesimpta, leukaemia treatment Scemblix, and cholesterol medicine Leqvio to generate $18 billion in peak sales, up from a previous forecast of $14 billion combined.

Shares fell 2.4% in morning trading in Switzerland. For investors, the question will be whether those three drugs can grow fast enough to offset lost sales as other drugs face competition from cheaper rivals entering the market

The upgrade comes as Novartis projected annual sales growth of 5% through 2031, slightly less ambitious than its previous guidance of between 5% and 6% through 2030, although it covers a different five-year period.

CEO Vas Narasimhan said the revised outlook reflected the expected entry of U.S. generic competition for Kisqali, a breast cancer treatment, in the second half of 2031.

Tune in at 11 a.m. ET as Novartis CEO Vas Narasimhan joins CNBC TV. Watch in real time on CNBC+ or the CNBC Pro stream.